|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on September 19, 2002; DOI 10.1182/blood-2002-06-1761.
IMMUNOBIOLOGY
From the Tenovus Research Laboratory and Medical
Oncology, Cancer Sciences Division, School of Medicine, General
Hospital, Southampton, United Kingdom; University of Wales, Department
of Medical Biochemistry, College of Medicine, Heath Park, Cardiff,
United Kingdom; Institute of Immunology Kashirskoye Shosse, Moscow,
Russia.
Despite the clinical success of anti-CD20 monoclonal antibody
(mAb) in the treatment of lymphoma, there remains considerable uncertainty about its mechanism of action. Here we show that the ability of mAbs to translocate CD20 into low-density,
detergent-insoluble membrane rafts appears to control how effectively
they mediate complement lysis of lymphoma cells. In vitro studies using
a panel of anti-B-cell mAbs revealed that the anti-CD20 mAbs, with one exception (B1), are unusually effective at recruiting human complement. Differences in complement recruitment could not be explained by the
level of mAb binding or isotype but did correlate with the redistribution of CD20 in the cell membrane following mAb ligation. Membrane fractionation confirmed that B1, unlike 1F5 and rituximab, was
unable to translocate CD20 into lipid rafts. In addition, we were able
to drive B1 and a range of other anti-B-cell mAbs into a
detergent-insoluble fraction of the cell by hyper-cross-linking with
an F(ab')2 anti-Ig Ab, a treatment that also conferred the ability to activate lytic complement. Thus, we have shown that an
important mAb effector function appears to be controlled by movement of
the target molecule into membrane rafts, either because a raft location
favors complement activation by mAbs or because rafts are more
sensitive to complement penetration.
(Blood. 2003;101:1045-1052) The success of the chimeric anti-CD20 monoclonal
antibody (mAb), rituximab (Ritux), in treating B-cell malignancies and,
more recently, autoimmune diseases has continued to focus attention on
antibody effector mechanisms in order to explain how this mAb operates
in vivo.1-4 What makes anti-CD20 mAbs so clinically effective is not clear, however, at least in vitro, they mediate both
complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) and, unlike many other
anti-B-cell mAbs, are also able to mediate growth arrest and apoptosis
in certain cell lines.5-9 At present, it is not known
which of these mechanisms predominates in vivo or in fact whether
anti-CD20 mAbs are able to use different effector mechanisms, according
to where the target cells are located or their stage of
differentiation. The most persuasive evidence supporting natural
effector (ADCC and CDC) mechanisms in the therapeutic response comes
from work in primates showing that an IgG4 variant of Ritux, unlike the clinically approved IgG1, was unable to deplete normal B
cells.10 Since this IgG4 variant would be unable to
recruit natural effectors effectively but should retain the binding and
cross-linking functions needed for any direct cytotoxic activity,
including the signaling of apoptosis, these data point toward CDC and
ADCC as the major effectors in vivo. However, in vitro experiments show
that signaling activity is often enhanced by hyper-cross-linking
either using anti-Ig antisera or Fc In contrast, understanding the role of complement in anti-CD20
therapy is more problematic, and while complement is consumed during
Ritux treatment and appears to be responsible for much of the
associated toxicity, its importance as an effector mechanism is still
controversial.14-19 One of the main arguments against complement being a major effector is that the therapeutic activity of
Ritux does not appear to correlate with the expression levels of the
complement defense molecules CD55 or CD59.15
Interestingly, however, a brief report of chronic lymphocytic leukemia
(CLL) patients receiving Ritux showed that cells circulating 8 weeks after treatment did have increased CD59 expression,
consistent with the idea that they had been subject to complement
selection.20 Furthermore, most studies on anti-CD20 mAb
effector mechanisms have tended to consider ADCC and CDC as separate
processes and thus exclude any possible cooperative activity, for
example, where complement opsonization might be important for
phagocytosis and regulation of immune responses. It is also unknown
whether products arising from complement activation, such as the
membrane attack complex (MAC), could have important signaling functions
via glycosylphosphatidylinositol (GPI)-linked receptors that
might modulate signaling activity provided by anti-CD20
mAbs.21,22
The CD20 molecule is without known function or ligand, and knock-out
mice show no obvious phenotype.23 It is a 33 to 37-kDa nonglycosylated surface phosphoprotein that is predicted to cross the
plasma membrane 4 times, leaving a single detectable extracellular loop
and the N- and C-termini inside the cell.24,25 CD20
probably exists in an oligomeric form in the plasma membrane, where it may either assist in, or directly contribute to, the formation of
cellular ion channels.26,27 Until recently, blocking
studies showed very limited epitope diversity in the extracellular loop of CD20, with only 2 overlapping epitopes, one recognized by the vast
majority of anti-CD20 mAbs, and a second recognized by a unique
reagent, 1F5.28 However, Deans and
colleagues26 have just revealed a more complex situation,
placing 16 anti-CD20 mAbs into 4 different subgroups according to their
ability to bind to a crucial alanine-X-proline motif in the CD20
extracellular loop. These mAbs also could be grouped by their ability
to translocate CD20 into the detergent-insoluble lipid microdomains,
generally known as "rafts" (most mAbs), trigger extensive homotypic
cellular adhesion (3 mAbs), or perform both of these activities (1 mAb). In our previous work we found that a similar panel of anti-CD20 mAbs could be subdivided into mAbs that were effective or not at
inducing CDC and speculated that these functions might be related to
the ability of the mAbs to translocate into membrane
rafts.29 In the current study we show a close relationship
between the ability of a mAb to translocate CD20 into lipid rafts
and to activate lytic complement. Thus, it appears that a key effector
function of a mAb may be related to its ability to redistribute target antigen into specific compartments of the plasma membrane.
Cell lines
Antibody production and labeling
CDC assay Serum for complement lysis was prepared as follows: blood from healthy volunteers was allowed to clot at room temperature for 30 to 60 minutes and then centrifuged at 900g for 20 minutes. Serum was harvested and then either used fresh or stored at 80°C. To determine the CDC activity of the various mAbs, elevated
membrane permeability was assessed using a rapid and simple propidium
iodide (PI) exclusion assay, as previously
described.36
Fluorescence resonance energy transfer analysis mAbs were directly conjugated to bisfunctional N-hydrosuccinimidyl (NHS)-ester derivatives of Cy3 and Cy5 (Amersham Biosciences, Little Chalfont, United Kingdom) as described in the manufacturer's instructions. The labeled mAb was isolated using a PD10-Sephadex G25 column. Molar ratios of coupling were determined spectrophotometrically from 552 = 150/mM/cm for Cy3,
650 = 250/mM/cm for Cy5, and
280 = 170/mM/cm for protein, and ranged from 5- to
8-fold excess dye/protein. Aggregates were removed by centrifugation.
Fluorescence resonance energy transfer (FRET) analysis was based on the method described previously.37 Cells were resuspended at 3 × 106 cells/mL in phosphate-buffered saline (PBS)/0.1% bovine serum albumin (BSA)/1% heat-inactivated mouse and human serum, and equimolar donor (Cy3)-conjugated and acceptor (Cy5)-conjugated mAbs were combined and added to the cell suspension (10 µg/mL, final). Cells were incubated for 50 minutes in the dark, on ice, or at 37°C. Each experiment included cells labeled with donor- and acceptor-conjugated mAbs after preincubation with a 20-fold molar excess of unconjugated mAbs, and cells labeled with donor- or acceptor-conjugated mAbs in the presence of equimolar unlabeled mAbs. FRET was assessed using flow cytometry on a FACSCalibur (BD Biosciences, San Jose, CA). The fluorescence intensities at 585 nm (FL2) and 650 nm (FL3), both excited at 488 nm, and the fluorescence intensity at 661 nm (FL4), excited at 635 nm, were detected and used to calculate FRET according to the equation below, where A is acceptor (Cy5) and D is donor (Cy3). All values obtained were corrected for autofluorescence: FRET = FL3(D, A) Correction parameters were obtained using data collected from single-labeled cells, and side scatter was used to gate out dead cells. FRET between donor and acceptor mAbs on the cells is expressed as acceptor sensitized emission at 488 nm.37 Larger FRET efficiencies suggest closer association of the donor and acceptor mAbs or a high density of acceptor mAbs in the vicinity of donor mAbs.38,39 Preparation of lipid raft fractions and Western blotting Monoclonal Ab (1 µg/106 cells) was added to cells at 37°C. Following 20 minutes' incubation, cells were pelleted and lysed in ice-cold 1.0% Triton X-100 in 2-[N-morpholino] ethanesulfonic acid (MES)-buffered saline (25 mM MES, pH 6.5, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 5 µg/mL aprotinin, 5 µg/mL leupeptin, 10 mM EDTA [ethylenediaminetetraacetic acid]). Lipid raft fractions were then prepared by sucrose density gradient centrifugation as described by Deans et al.40 Fractions were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred onto polyvinylidenefluoride membranes, and incubated with primary antibody (mouse anti-CD20, clone 7D1, or anti-Lyn rabbit polysera; Serotec, United Kingdom), followed by horseradish-peroxidase-conjugated secondary antibody (Amersham Biosciences). Blots were visualized using ECL+plus (Amersham Biosciences).Assessment of raft-associated antigen by Triton X-100 insolubility As a rapid assessment of antigen presence in raft microdomains, we used a flow cytometry method based on Triton X-100 insolubility at low temperatures, as described previously.41,42 In brief, cells were washed in RPMI/1% BSA and resuspended at 2.5 × 106/mL. Cells were then incubated with 10 µg/mL of fluorescein isothiocyanate (FITC)-conjugated mAbs for 15 minutes at 37°C, washed in cold PBS/1% BSA/20 mM sodium azide, and then the sample divided in half. One half was maintained on ice to allow calculation of 100% surface antigen levels, while the other was treated with 0.5% Triton X-100 for 15 minutes on ice to determine the proportion of antigens remaining in the insoluble raft fraction. Cells were then maintained at 4°C throughout the remainder of the assay, washed once in PBS/BSA/azide, resuspended, and assessed by flow cytometry as detailed above. Similar results were obtained using indirect methods of detection. To determine the constitutive level of raft association of target antigens, cells were first treated with 0.5% Triton X-100 for 15 minutes on ice and washed in PBS/BSA/azide prior to binding of FITC-labeled mAbs. To assess whether more antigen could be moved into the Triton X-100-insoluble fraction by additional cross-linking, cells were incubated with FITC-mAb as before, washed, and then divided into 4 samples. Two of these samples were incubated with goat anti-mouse Ig F(ab')2 fragments for 15 minutes on ice. After washing, one of the cross-linked and one of the non-cross-linked samples were lysed in Triton X-100 and washed as detailed above, prior to flow cytometry.Transfection of YFP-Hu CD20 and confocal microscopy A chimera of yellow fluorescent protein (YFP) fused to the C-terminal region of human CD20 (YFP-Hu20) was constructed by fusing full-length human CD20 into the pEYFP-C1 plasmid (Clontech, Basingstoke, United Kingdom) via XhoI and BamHI sites. YFP-Hu20 transfections of BCL1-3B3 cells were carried out using the GenePorter reagent (Gene Therapy System, San Diego, CA) and transfectants selected with geneticin (Invitrogen, Paisley, United Kingdom) and identified by flow cytometry.For visual redistribution studies, cells were stimulated with mAbs (10 µg/mL) for 20 minutes at room temperature. Cells were then cytospun, fixed (3.7% paraformaldehyde), washed, and mounted in Mowiol (Calbiochem-Novabiochem, San Diego, CA) with 0.1% Citifluor (Agar Scientific, Stanstead, United Kingdom). YFP-HuCD20 clustering was visualized using a Leica SP2 confocal microscope (Bannockburn, IL).
CD20 mAb mediates potent recruitment of complement Recently, we have been struck by the unusual potency with which CD20 mAbs recruit human complement for the lysis of B-cell lymphoma cells. Figure 1 shows CDC results for a panel of IgG1 and IgG2a isotype mAbs directed at CD20, CD37, CD38, and MHCII. Ritux (chimeric Ab, with human IgG1 constant domains) is
included as a positive control. Against both Daudi and EHRB cells, the rodent anti-CD20 mAbs were consistently the most active of these reagents in CDC, usually mediating lysis of approximately 90% of the
target cells. Such results cannot be explained by the relative levels
of binding, because flow cytometric analysis showed that the anti-MHCII
mAb bound at the highest levels (Figures 1B and 5 show the mean
fluorescence intensity [MFI] of these mAbs) and yet were not the most
active. The differences in potency were most striking when comparing
IgG1 isotype mAbs, because under these conditions only the CD20
reagents initiated detectable CDC (18% and 90% lysis of Daudi and
EHRB cells, respectively).
Potency of different anti-CD20 mAbs in complement-mediated lysis To investigate whether this high CDC activity was a property of all anti-CD20 mAbs, we compared a large panel of anti-CD20 mAbs that included the clinically relevant Ritux and B1 reagents. Figure 2 shows that the mAbs could be divided into 2 distinct groups by this assay: the first, which included Ritux, 1F5, and HI47, contained reagents that were potent in CDC; the second, which included AT80, 2H7, LT20, and B1, contained those with relatively poor cytolytic activity. In most cases such activity is explicable on the basis of mAb isotype with human IgG1, mouse IgG2a, and IgG3 performing well, and mouse IgG1 and IgG2b performing poorly. It is important to bear in mind that even this poorly performing group was surprisingly active given that mouse IgG1 mAbs are generally considered unable to recruit human complement.43,44 Indeed, these mAbs were more active than those carrying the mouse IgG2a isotype, directed to the CD37 and CD38 antigens. The one exception in this distribution was B1, which, despite being a mouse IgG2a, performs poorly in CDC. It also should be noted that kinetics of CDC were examined in preliminary experiments, which revealed that optimal lysis with 1F5 was observed as early as 5-10 minutes after the addition of serum. However, our CDC assays were routinely performed for 30-45 minutes to allow suboptimal mAbs to induce their maximal CDC activity. Longer durations (ie, > 45 minutes) were not assessed to minimize other forms of cell death, for example, apoptosis.
Binding properties of CD20 mAbs on B-cell lines We next investigated the relative binding activity of these mAbs using radiolabeled F(ab')2 fragments to see if this might explain the differences in complement activity. Figure 3A shows saturation curves that confirmed the binding constants for Ritux (5-8 × 10-9 M), B1 (3-6 × 10-9 M), and 1F5 (1-3 × 10-8 M) on Daudi and EHRB cells. Each mAb gave a range of affinities, indicating interexperimental variation and binding activity on different cell lines. Radiolabeled IgG gave similar curves (results not shown, except for 1F5 IgG binding to EHRB cells), showing that the Fc region was not involved in binding to the cells. The surprising finding was that B1 and Ritux, despite binding to the same target CD20 loop with high affinity, saturated at different levels, with Ritux binding almost twice as many molecules on each cell. 1F5 has a weaker binding affinity but, despite generating flatter binding curves, eventually reaches similar levels of binding to those achieved by Ritux. These differences are the subject of ongoing investigation. Despite these distinct binding patterns, we do not believe that they explain the observed differences in CDC activity, mainly because 1F5 and Ritux gave clear cytotoxic activity at concentrations well below their binding maxima. For example, Figure 2 shows that even at 0.08 µg/mL, a concentration that would have achieved less than 20% Ritux or 10% 1F5 saturation (Figure 3A), we recorded at least 50% lysis for Ritux and 1F5. In contrast, B1 could achieve this level of lytic activity only when added at 10 µg/mL, representing 125 times less potency. We conclude that at saturation, B1 is capable of reaching levels on the cell that should mediate CDC as effectively as 1F5 or Ritux.
During this investigation we performed microscopic examination of anti-CD20 mAb binding to cells using FITC-mAb. These experiments revealed clear differences in the distribution of CD20 bound by the different mAbs, in that B1 bound over the cell surface homogeneously, while other anti-CD20 mAbs appeared to bind in clusters, revealed by punctate staining (data not shown). In order to investigate this phenomenon more closely, we used a mouse cell line (BCL1-3B3) transfected to express YFP-tagged human CD20, which bypasses any variation in mAb-FITC conjugation and the need of secondary amplifying reagents. These data reveal (Figure 3B) that, as in the Burkitt lines, B1 caused minimal redistribution of CD20 upon binding, while other anti-CD20 mAbs such as Ritux and 1F5 caused marked clustering of YFP-CD20. Redistribution of CD20 and anti-CD20 mAbs on target cells The reorganization of CD20 in the plasma membrane following binding by mAbs is likely to be important in providing the appropriate distribution of Fc regions for the recruitment of C1q and the triggering of the classical pathway of complement. To examine this reorganization further, we used FRET analysis to measure the molecular proximity of anti-CD20 mAbs on intact Daudi and EHRB cells. In these experiments, separate batches of each anti-CD20 mAb were labeled with Cy3 or Cy5 and energy transfer values obtained for 50:50 mixtures of Cy3- and Cy5-labeled mAbs (eg, B1 Cy3 + B1 Cy5). For comparison, 3 other non-CD20 mAb specificities were similarly assessed (MHCII, CD37, and CD38). A high FRET value indicates close proximity of neighboring Cy3- and Cy5-labeled mAbs38,39 and can be caused either by mAb binding to a surface molecule that is expressed at high density or by mAb ligation causing redistribution and closer association of the molecular target. Figure 4A shows histograms from a typical experiment, illustrating FRET data for Ritux and B1 (open histograms) compared with controls (shaded histograms). The clear shift in the open histogram with Ritux represents demonstrable FRET due to the close proximity of the acceptor and donor-labeled mAbs. In comparison, B1 generated insignificant levels of FRET. These experiments were performed 3 times with the panel, and the results are presented as a bar chart in Figure 4B. The results show that while Ritux and 1F5 were very effective in this assay, with Ritux recording between 50 and 70 FRET units on EHRB and Daudi cells, respectively, B1, which was poor at activating complement, was completely inactive in generating a FRET signal. In this regard, it performed like anti-CD37 and anti-CD38 mAbs, other targets that are relatively poor in CDC. For both Ritux and 1F5, the levels of FRET were higher at 37°C than at 4°C. Because the plasma membrane is more mobile at higher temperatures, these results are consistent with FRET values being dependent on molecular reorganization in the plasma membrane rather than on antigen density. Conversely, mAb binding to MHCII gave only a modest level of FRET, which was not greatly enhanced at 37°C, indicating that these FRET values were predominantly due to the high surface expression of MHCII. Thus, these results indicate a good correlation between the ability of a mAb to perform CDC and to mediate FRET.
On the basis of this information, we decided to investigate the association of CD20 with lipid rafts. It is known that, without cross-linking, CD20 is not associated with rafts and is readily soluble in nonionic detergents such as TX-100, at low temperatures.40,45 We investigated the distribution of CD20 between the raft and nonraft membrane fractions using the sucrose gradient fractionation method described by Deans and colleagues.40 Figure 4C shows that following sucrose gradient fractionation of Triton X-100-solubilized Daudi cells, CD20 molecules are confined to high-density fractions 6-8. Cells treated with B1 for 30 minutes showed a similar CD20 distribution to untreated cells, in fractions 6-8. In contrast, cells treated with Ritux or 1F5 showed a distinct shift in CD20 distribution with a significant proportion now found in the lower density fractions 4, or 3 and 4, respectively, coincident with where membrane rafts are expected to occur. To verify the location of rafts in our preparations, we reprobed the membranes for Lyn (Figure 4C), a known raft marker that, as expected, was found in the low-density fractions.3-5 Thus, it appears that the ability of anti-CD20 mAbs to demonstrate FRET and activate complement shows a tight correlation with the ability to redistribute CD20 into membrane rafts. The distinct redistribution of CD20 to fraction 4 following cross-linking with Ritux, compared with fractions 3 and 4 with 1F5 treatment, was a consistent but unexplained finding (Figure 4B). CD20 becomes Triton X-100-insoluble when cross-linked by mAbs To continue these investigations and study a range of other antigen specificities without having to perform sucrose gradient sedimentation and Western blotting, we moved to a flow cytometric method in which cells are treated with dilute Triton X-100 before or after staining with fluorescent mAbs.41,42 Under the conditions used, it is possible to remove nonraft lipid and most of the cytoplasm from the cells, leaving only the insoluble parts of the cell together with the lipid rafts. Figure 5 shows staining of Daudi and EHRB cells, first using mAbs on intact cells (solid bars), then on cells that have been treated with Triton X-100 before staining with mAbs (open bars, not shown for EHRB), and finally for cells stained with mAbs and then treated with Triton X-100 (hatched bars). The results clearly show that in all cases except one, treating with Triton X-100 removes all cell-associated molecules, making them unavailable for staining. The one exception is Campath (CD52), which is GPI-linked and therefore constitutively associated with the outer leaflet of rafts. The GPI-linked molecules CD55 and CD59 are similarly retained following such treatment (data not shown). These results are consistent with raft material being retained with the Triton X-100-treated cells in this technique. EHRB cells do not express GPI-linked proteins and therefore do not express CD52. In contrast to this situation, when the cells were stained with these mAbs before being treated with Triton X-100 (hatched bars), we found that most anti-CD20 mAbs remained with the cells. Furthermore, B1, the one anti-CD20 mAb that did not move CD20 into rafts, also failed to remain with the Triton X-100-treated cells. All other mAb specificities, with the exception of CD52, failed to remain with the Triton X-100 insoluble fraction.
Given that the ability of anti-CD20 mAbs to move CD20 into rafts
appeared to correlate with the ability to cross-link neighboring CD20
molecules, we next asked if more surface molecules became associated
with the Triton X-100 insoluble fraction as they were cross-linked.
Figure 6A shows very clearly that as the
primary mAbs became cross-linked with F(ab')2 fragments of
polyclonal anti-Ig Abs, so more molecules were able to remain with the
cells following treatment with Triton X-100. Under these conditions, all mAbs, including B1, showed a proportion of binding remaining following detergent treatment. In the most striking case, 80% of MHCII
molecules remained with the Triton X-100-treated cells following
hyper-cross-linking of the mAbs, whereas only 4% remained when
additional cross-linking was not added. In contrast, B1 appeared the
most reluctant to move into the insoluble fraction, and in this case
about 25% of the mAbs remained after the detergent treatment.
Monoclonal antibodies mediate complement lysis more efficiently when transferred into the detergent-insoluble fraction of the cell membrane Finally, we asked if cross-linking a primary mAb in this way not only shifted the target to the more insoluble part of the plasma membrane but also changed the ability of the mAb to activate complement. Figure 6B shows that for all mAbs investigated, additional cross-linking with F(ab')2 anti-Ig promoted CDC. This was particularly striking in the case of the anti-MHCII IgG1 mAb, which, without cross-linking, was unable to lyse cells but became as potent as Ritux when cross-linked with 5 µg/mL F(ab')2 anti-Ig. Similar potentiation in CDC was obtained when the IgG2a mAb against CD37 (WR17) and CD38 (1B4) were treated with just 1 µg/mL F(ab')2 anti-Ig. Interestingly, the B1 mAb (IgG2a) against CD20, which was least inclined to move into the Triton X-100 insoluble fraction following cross-linking (Figure 6A), also showed an appreciable improvement in CDC activity following the addition of the polyclonal cross-linker. Thus, in each case, a treatment that is known to drive Ab:Ag complexes into a detergent-insoluble fraction, which includes membrane rafts, improves the ability of mAbs to recruit lytic complement.
The ability of mAbs to recruit and activate complement at the cell surface is dependent not only on isotype and target density but also the lateral mobility of Ab:Ag complexes in the plasma membrane and the distance between the target epitope and the lipid bilayer.46 Thus, the specificity of mAbs can have profound and subtle influences on the efficiency with which complement is recruited. Here we have shown that anti-CD20 mAbs are unusually effective at recruiting complement for the lysis of neoplastic B cells and that this activity is closely linked to the ability of the mAbs to translocate CD20 into membrane rafts following ligation.26,40,45 All but one of the anti-CD20 mAbs were effective in mediating CD20 raft translocation and in recruiting human complement in CDC assays. The exception, B1, was unable to deliver CD20 into rafts and, despite being of a complement-activating isotype (IgG2a) and causing C1s and C3 deposition equivalent to 1F5 in solid-phase enzyme-linked immunosorbent assay experiments (data not shown), failed to lyse cells in CDC. It is not clear why translocation of Ab:Ag complexes into lipid rafts should influence the ability of mAbs to activate complement so markedly, even to the point where mouse IgG1 anti-CD20 isotypes, which normally activate human complement comparatively poorly, were able to lyse malignant B cells.43,44 Because of the requirement for at least 2-headed binding to engage and activate C1q, the most straightforward explanation is that concentrating mAbs into a comparatively small area of the plasma membrane provides an ideal density of juxtaposed Fc regions for engaging the C1q heads, thereby triggering the classical complement pathway.47,48 Our FRET data give good support for this suggestion, showing that ligation of CD20 by complement-lytic mAbs is associated with a sharp rise in FRET, consistent with the Ab:Ag complexes becoming redistributed into rafts. A second possibility is that the cholesterol-rich environment provided by rafts is advantageous for complement activation through C3 deposition or by providing a region of the membrane that is more susceptible to penetration by MAC, perhaps because the lipid is more rigid or the MAC are less likely to be removed by internalization. Previous work supports this, showing that red blood cells became more susceptible to lysis as their cholesterol content was increased.49,50 We are currently investigating these 2 possibilities by asking whether the relative potency of anti-CD20 mAbs lies in their ability to activate C1, that is, provide an optimal Fc binding platform, or in the efficiency with which they use MAC, that is, membrane penetration. It is interesting that most complement-defense molecules, being GPI-linked, are constitutively associated with rafts and consequently ideally placed to protect cells from any damage focused on the rafts. Cross-linking of cell-surface antigen by fluid-phase antibody, with subsequent aggregation and lateral movement of Ab:Ag complexes, has long been associated with the phenomenon of antigenic modulation, whereby the cell acquires resistance to complement lysis induced by that antibody.51 This process can be inhibited with azide or by using univalent mAbs that are unable to provide cross-linking activity.52 With many target antigens, such as the thymus leukemia antigen TL and the B-cell receptor BCR, the redistribution of Ab:Ag complexes is followed by their internalization and degradation, leaving the cell free of target antigen. Thus, antigenic modulation and internalization often has been cited as one of the reasons certain mAb specificities fail to perform in the clinic and may partly explain why anti-CD20 mAbs, which do not modulate or internalize even in vivo,53 are effective in CDC and clinically successful. Interestingly, we have shown previously that when the target antigen concerned is the BCR on leukemic B lymphoblasts, anti-complement modulation was established in 2 to 5 minutes following exposure to anti-Ig at 37°C and appeared to require only limited surface reorganization of Ab:Ag complexes on the cell surface.54,55 This modulated state occurred sufficiently rapidly to protect the cell when lytic syngeneic complement was present and persisted in the presence of "patched" Ab:Ag complexes on the surface. It is not clear at this stage what relationship this patched material has to lipid rafts, but recent cell signaling studies show that the BCR can become raft-associated following cross-linking in some B-cell types. The situation in the current work appears quite different, since here we find that redistribution of anti-CD20:CD20 complexes on the cell surface was required for full CDC activity. Furthermore, the complement-activating activity of other anti-B-cell mAbs (anti-CD37, -CD38, and -MHCII) also was promoted following cross-linking with F(ab')2 anti-Ig and movement into the detergent insoluble fraction of the plasma membrane. Thus, our earlier observations, taken in conjunction with the present report, suggest that a critical decision may be made when Ab:Ag complexes, presumably with their attached C1, are reorganized into lipid rafts. Complement lysis is either potentiated, as in the case of anti-CD20 and some other anti-B-cell mAbs (current work), or it is diminished, as can occur with anti-BCR and anti-TL Abs in certain cells. Further work will be required to understand the processes that control these molecular decisions. Recently, Polyak and Deans26 showed that recognition of CD20 by most mAbs depends on an alanine and a proline at positions 170 and 172, respectively, in the extracellular loop of human CD20. Simply introducing these 2 residues into the equivalent positions of the mouse sequence reconstituted the binding of a range of mAbs, including B1 and Ritux. However, although this work underlined the subtleties in epitope specificity for anti-CD20 mAbs and showed that mAbs with apparently similar specificities can have quite distinct functions, it did not reveal which features of a mAb controlled translocation of CD20 into rafts. CD20 is an unusual plasma membrane molecule in terms of its ability to translocate into lipid rafts following ligation by mAbs.40,45 Most surface molecules either are constitutively associated with rafts, such as GPI-linked receptors, or remain excluded from rafts even following mAb ligation. In the current work we confirmed CD52 to be constitutively present in rafts, while CD37, CD38, and MHCII are excluded even after ligation by mAbs. There are only 2 published examples, B1 and Bly1, of mAbs that do not deliver CD20 into rafts.26 However, data presented here suggest that following hyper-cross-linking with polyclonal F(ab')2 anti-Ig, B1 was at least partially translocated into the detergent-insoluble fraction of the cell. Simultaneously, B1 became more active in CDC and interestingly, hyper-cross-linking other B-cell targets in this way, such as MHCII, CD37, and CD38, also delivered them into a detergent-insoluble fraction and improved CDC activity. Thus, movement of membrane proteins into rafts appears directly related to the degree of cross-linking provided by the ligating agents, and we suggest that this unusual property of CD20 in part relates to the degree of cross-linking that most anti-CD20 mAbs are able to provide to CD20 on the surface of B cells. An alternative explanation for the unusual activity of CD20 may relate to its topology within the plasma membrane. Evidence from a number of studies has suggested that CD20 exists as a multimer in the surface membranes of B cells, with 4 self-associated CD20 monomers or with a mixture of CD20 monomers and other plasma membrane molecules.26,27 Polyak et al45 identified a short stretch of membrane proximal sequence in the cytoplasmic carboxyl tail of CD20 that appears important for redistribution into rafts following mAb ligation. One postulated function for such a motif is promoting oligomerization of CD20, perhaps via protein-protein interactions. Thus, one may envisage that CD20 resides in nonraft regions of the membrane, perhaps as multimers, as inactive or incomplete ion channels. Ligation by most anti-CD20 mAbs causes efficient cross-linking of neighboring molecular complexes, resulting in aggregation of CD20 molecules and translocation into rafts. However, perhaps in the case of rare mAbs such as B1, the recognized epitope favors a different mode of binding. Studies using radiolabeled Fab' (not shown) and F(ab')2 fragments (Figure 3) show that B1 binds to cells bivalently. The most logical explanation for our findings is that B1 binds 2 CD20 molecules within a single CD20 multimer, while other anti-CD20 mAbs tend to engage neighboring CD20 multimers. A similar situation has been described for anti-V region mAb binding to surface IgM, with some mAbs preferring to bind between BCR and others engaging both Fab arms on the same BCR.56 The functional consequences of such binding were seen in the readiness with which these 2 types of reagent caused redistribution of the BCR into patches and caps and in the propensity with which they evoked apoptosis.57 Interestingly, in the current work, binding studies showed that at equilibrium, approximately half as many radiolabeled B1 molecules bound as did Ritux and 1F5 (Figure 3A), supporting the proposal that B1 binds in an unusual configuration. It is not known at this time whether translocation of CD20 into membrane rafts is important for the activity of anti-CD20 mAbs in patients. Although the potency of Ritux indicates that mAbs that move CD20 into rafts can be highly therapeutic, there is currently little convincing evidence that complement plays a significant part in this activity.14,15 However, what is not clear is whether a humanized version of B1, because it does not move CD20 into rafts, would provide a more or less potent reagent. While B1 has been used extensively in clinical trials, its role has been as a carrier for radioactive 131I, tositumomab, with little consideration for its potential intrinsic therapeutic activity.58 Only an extremely limited amount of patient data are available for unlabeled B1, acquired as part of a study to measure the contributions of the mAbs and the targeted radioisotope in the therapeutic activity of radioiodinated B1.59 Interestingly, the results show that, even as a "naked" mAb, B1 is capable of inducing objective responses in NHL patients, including a number of complete responses. Thus, although the study also showed that B1 generated a number of human anti-mouse antibody responses, it indicated a surprising level of activity for a rodent mAb. For the future, a humanized version of B1 might be an interesting reagent for development, since it should have many of the beneficial properties of Ritux, including the ability to induce ADCC29,60 and apoptosis7,8,29,60 (and M.S.C. et al., unpublished results, June 2001), but might avoid some of the adverse toxic activity that arises when Ritux activates complement.14
We wish to express our gratitude to all members of the Tenovus Cancer Laboratory who provided expert technical support and valuable discussion. We are also indebted to Drs Richard Miller, Geoff Hale, and Fabio Malavasi for generously providing mAbs. We wish to thank Mr Roger Alston (Biomedical Imaging Unit) for assistance with confocal microscopy.
Submitted June 19, 2002; accepted September 12, 2002.
Prepublished online as Blood First Edition Paper, September 19, 2002; DOI 10.1182/blood-2002-06-1761.
Supported by the Biotechnology and Biological Sciences Research Council (BBSRC), Tenovus of Cardiff, Cancer Research United Kingdom, and the Leukaemia Research Fund.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Martin J. Glennie, Tenovus Laboratory, Cancer Sciences Division, General Hospital, Southampton, SO16 6YD, United Kingdom; e-mail: mjg{at}soton.ac.uk.
1. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med. 1999;134:445-450[CrossRef][Medline] [Order article via Infotrieve]. 2. Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today. 2000;21:403-410[CrossRef][Medline] [Order article via Infotrieve]. 3. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29:2-9[Medline] [Order article via Infotrieve]. 4. Leandro MJ, Edwards JCW, Cambridge G. Clinical outcome on 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002;61:0-5.
5.
Clark EA, Shu G, Ledbetter JA.
Role of the Bp35 cell surface polypeptide in human B-cell activation.
Proc Natl Acad Sci U S A.
1985;82:1766-1770 6. Tedder TF, Forsgren A, Boyd AW, Nadler LM, Schlossman SF. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol. 1986;16:881-887[Medline] [Order article via Infotrieve].
7.
Shan D, Ledbetter JA, Press OW.
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.
Blood.
1998;91:1644-1652 8. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000;48:673-683[CrossRef][Medline] [Order article via Infotrieve]. 9. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis. 2000;26:133-143[CrossRef][Medline] [Order article via Infotrieve]. 10. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans. 1997;25:705-708[Medline] [Order article via Infotrieve].
11.
Ghetie MA, Bright H, Vitetta ES.
Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.
Blood.
2001;97:1392-1398 12. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443-446[CrossRef][Medline] [Order article via Infotrieve].
13.
Cartron G, Dacheux L, Salles G, et al.
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc 14. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001;115:807-811[CrossRef][Medline] [Order article via Infotrieve].
15.
Weng WK, Levy R.
Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Blood.
2001;98:1352-1357
16.
Bellosillo B, Villamor N, Lopez-Guillermo A, et al.
Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species.
Blood.
2001;98:2771-2777
17.
Idusogie EE, Wong PY, Presta LG, et al.
Engineered antibodies with increased activity to recruit complement.
J Immunol.
2001;166:2571-2575 18. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol. 2000;51:634-641[CrossRef][Medline] [Order article via Infotrieve].
19.
Golay J, Zaffaroni L, Vaccari T, et al.
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
Blood.
2000;95:3900-3908 20. Bannerji RPM, Flinn IW. Cell surface complement inhibitors CD55 and CD59 may mediate chronic lymphocytic leukemia (CLL) resistance to rituximab therapy [abstract]. Blood. 2000;96:164. 21. Morgan BP, van den Berg CW, Davies EV, Hallett MB, Horejsi V. Cross-linking of CD59 and of other glycosyl phosphatidylinositol-anchored molecules on neutrophils triggers cell activation via tyrosine kinase. Eur J Immunol. 1993;23:2841-2850[Medline] [Order article via Infotrieve].
22.
Murray EW, Robbins SM.
Antibody cross-linking of the glycosylphosphatidylinositol-linked protein CD59 on hematopoietic cells induces signaling pathways resembling activation by complement.
J Biol Chem.
1998;273:25279-25284 23. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics. 1998;48:125-132[CrossRef][Medline] [Order article via Infotrieve].
24.
Stamenkovic I, Seed B.
Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein.
J Exp Med.
1988;167:1975-1980 25. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. Embo J. 1988;7:711-717[Medline] [Order article via Infotrieve].
26.
Polyak MJ, Deans JP.
Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure.
Blood.
2002;99:3256-3262
27.
Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF.
Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.
J Cell Biol.
1993;121:1121-1132 28. Tedder T, Penta A. Structure of the CD20 antigen and gene of human and mouse B cells: use of transfected cell lines to examine the workshop panel of antibodies. In: Knapp W,Dorken B,Gilks W,Rieber E,Schmidt R,von dem Borne A, eds. Leukocyte typing IV: white cell differentiation antigens. Oxford United Kingdom: Oxford University Press; 1989:48-50. 29. Cragg MS, Asidipour A, O'Brien L, et al. Opposing properties of anti-CD20 mAb. In: Mason D,Simmons D,Schwartz-Albiez R, et al., eds. Leucocyte typing VII. Oxford United Kingdom: Oxford University Press; 2002:95-96. 30. Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol. 1989;7:1027-1038[Abstract]. 31. Moore K, Cooper SA, Jones DB. Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy. J Pathol. 1987;152:13-21[CrossRef][Medline] [Order article via Infotrieve]. 32. Funaro A, De Monte LB, Dianzani U, Forni M, Malavasi F. Human CD38 is associated to distinct molecules which mediate transmembrane signaling in different lineages. Eur J Immunol. 1993;23:2407-2411[Medline] [Order article via Infotrieve]. 33. Xia MQ, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol. 1993;30:1089-1096[CrossRef][Medline] [Order article via Infotrieve]. 34. Glennie MJ, McBride HM, Worth AT, Stevenson GT. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments. J Immunol. 1987;139:2367-2375[Abstract].
35.
Tutt AL, French RR, Illidge TM, et al.
Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.
J Immunol.
1998;161:3176-3185 36. Cragg MS, Howatt WJ, Bloodworth L, Anderson VA, Morgan BP, Glennie MJ. Complement mediated cell death is associated with DNA fragmentation. Cell Death Differ. 2000;7:48-58[CrossRef][Medline] [Order article via Infotrieve]. 37. Pfeiffer A, Bottcher A, Orso E, et al. Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts. Eur J Immunol. 2001;31:3153-3164[CrossRef][Medline] [Order article via Infotrieve]. 38. Szollosi J, Tron L, Damjanovich S, Helliwell SH, Arndt-Jovin D, Jovin TM. Fluorescence energy transfer measurements on cell surfaces: a critical comparison of steady-state fluorimetric and flow cytometric methods. Cytometry. 1984;5:210-216[CrossRef][Medline] [Order article via Infotrieve]. 39. Tron L, Szollosi J, Damjanovich S, Helliwell SH, Arndt-Jovin DJ, Jovin TM. Flow cytometric measurement of fluorescence resonance energy transfer on cell surfaces: quantitative evaluation of the transfer efficiency on a cell-by-cell basis. Biophys J. 1984;45:939-946[Medline] [Order article via Infotrieve].
40.
Deans JP, Robbins SM, Polyak MJ, Savage JA.
Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment.
J Biol Chem.
1998;273:344-348 41. Albrecht DL, Mills JW, Noelle RJ. Membrane Ig-cytoskeletal interactions, III: receptor cross-linking results in the formation of extensive filamentous arrays of vimentin. J Immunol. 1990;144:3251-3256[Abstract]. 42. Turner CE, Shotton DM. Effects of capping on the non-ionic detergent solubility of rat thymocyte glycoproteins. Eur J Cell Biol. 1989;50:324-332[Medline] [Order article via Infotrieve]. 43. Neuberger MS, Rajewsky K. Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol. 1981;11:1012-1016[Medline] [Order article via Infotrieve].
44.
Azeredo da Silveira S, Kikuchi S, Fossati-Jimack L, et al.
Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody.
J Exp Med.
2002;195:665-672
45.
Polyak MJ, Tailor SH, Deans JP.
Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment.
J Immunol.
1998;161:3242-3248 46. Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol. 1988;18:1507-1514[Medline] [Order article via Infotrieve]. 47. Golan MD, Burger R, Loos M. Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies. J Immunol. 1982;129:445-447[Abstract].
48.
Borsos T, Rapp HJ.
Complement fixation on cell surfaces by 19S and 7S antibodies.
Science.
1965;150:505-506 49. Cohen AM, Shinitzky M. Modulation of complement lysis of human erythrocytes by the membrane lipid viscosity. Vox Sang. 1982;43:23-27[Medline] [Order article via Infotrieve]. 50. Silverman BA, Weller PF, Shin ML. Effect of erythrocyte membrane modulation by lysolecithin on complement-mediated lysis. J Immunol. 1984;132:386-391[Abstract]. 51. Stackpole CW, Cremona P, Leonard C, Stremmel P. Antigenic modulation as a mechanism for tumor escape from immune destruction: identification of modulation-positive and modulation-negative mouse lymphomas with xenoantisera to murine leukemia virus gp70. J Immunol. 1980;125:1715-1723[Medline] [Order article via Infotrieve]. 52. Glennie MJ, Stevenson GT. Univalent antibodies kill tumour cells in vitro and in vivo. Nature. 1982;295:712-714[CrossRef][Medline] [Order article via Infotrieve].
53.
Press OW, Appelbaum F, Ledbetter JA, et al.
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas.
Blood.
1987;69:584-591 54. Gordon J, Stevenson GT. Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis, II: relationship to redistribution of the antigen. Immunology. 1981;42:13-17[Medline] [Order article via Infotrieve]. 55. Gordon J, Anderson VA, Stevenson GT. Loss of surface-bound antibody accompanying the anti-complementary modulation of leukemic B cell immunoglobulin: contrasting effects of antibodies directed against idiotypic and constant regions. J Immunol. 1982;128:2863-2869[Medline] [Order article via Infotrieve]. 56. Elliott TJ, Glennie MJ, McBride HM, Stevenson GT. Analysis of the interaction of antibodies with immunoglobulin idiotypes on neoplastic B lymphocytes: implications for immunotherapy. J Immunol. 1987;138:981-988[Abstract]. 57. Cragg MS, Zhang L, French RR, Glennie MJ. Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells. Br J Cancer. 1999;79:850-857[CrossRef][Medline] [Order article via Infotrieve].
58.
Kaminski MS, Estes J, Zasadny KR, et al.
Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.
Blood.
2000;96:1259-1266
59.
Davis MA, Kaminski MS, Leonard JP, et al.
Results of a randomized study of Bexxar (Tositumomab and Iodine I131 Tositumomab) vs unlabeled Tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma (NHL) [abstract].
Blood.
2001;98:3503 60. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002;51:15-24[CrossRef][Medline] [Order article via Infotrieve].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  T. M. Illidge, M. Bayne, N. S. Brown, S. Chilton, M. S. Cragg, M. J. Glennie, Y. Du, V. Lewington, J. Smart, J. Thom, et al. Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy Blood, February 12, 2009; 113(7): 1412 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Minard-Colin, Y. Xiu, J. C. Poe, M. Horikawa, C. M. Magro, Y. Hamaguchi, K. M. Haas, and T. F. Tedder Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc{gamma}RI, Fc{gamma}RIII, and Fc{gamma}RIV Blood, August 15, 2008; 112(4): 1205 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Meyer zum Buschenfelde, Y. Feuerstacke, K. S. Gotze, K. Scholze, and C. Peschel GM1 Expression of Non-Hodgkin's Lymphoma Determines Susceptibility to Rituximab Treatment Cancer Res., July 1, 2008; 68(13): 5414 - 5422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. V. Beum, M. A. Lindorfer, F. Beurskens, P. T. Stukenberg, H. M. Lokhorst, A. W. Pawluczkowycz, P. W. H. I. Parren, J. G. J. van de Winkel, and R. P. Taylor Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis J. Immunol., July 1, 2008; 181(1): 822 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Walshe, S. A. Beers, R. R. French, C. H. T. Chan, P. W. Johnson, G. K. Packham, M. J. Glennie, and M. S. Cragg Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling J. Biol. Chem., June 20, 2008; 283(25): 16971 - 16984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Koslowski, U. Sahin, K. Dhaene, C. Huber, and O. Tureci MS4A12 Is a Colon-Selective Store-Operated Calcium Channel Promoting Malignant Cell Processes Cancer Res., May 1, 2008; 68(9): 3458 - 3466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Li, S. Shi, W. Qian, L. Zhao, D. Zhang, S. Hou, L. Zheng, J. Dai, J. Zhao, H. Wang, et al. Development of Novel Tetravalent Anti-CD20 Antibodies with Potent Antitumor Activity Cancer Res., April 1, 2008; 68(7): 2400 - 2408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Macor, C. Tripodo, S. Zorzet, E. Piovan, F. Bossi, R. Marzari, A. Amadori, and F. Tedesco In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab Cancer Res., November 1, 2007; 67(21): 10556 - 10563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Du, H. Wang, C. Zhong, B. Peng, M. Zhang, B. Li, S. Huo, Y. Guo, and J. Ding Structural Basis for Recognition of CD20 by Therapeutic Antibody Rituximab J. Biol. Chem., May 18, 2007; 282(20): 15073 - 15080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Williams, J. J. Densmore, A. W. Pawluczkowycz, P. V. Beum, A. D. Kennedy, M. A. Lindorfer, S. H. Hamil, J. C. Eggleton, and R. P. Taylor Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia J. Immunol., November 15, 2006; 177(10): 7435 - 7443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Teeling, W. J. M. Mackus, L. J. J. M. Wiegman, J. H. N. van den Brakel, S. A. Beers, R. R. French, T. van Meerten, S. Ebeling, T. Vink, J. W. Slootstra, et al. The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20 J. Immunol., July 1, 2006; 177(1): 362 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. van Meerten, R. S. van Rijn, S. Hol, A. Hagenbeek, and S. B. Ebeling Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity. Clin. Cancer Res., July 1, 2006; 12(13): 4027 - 4035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Alfonso-Perez, S. Lopez-Giral, N. E. Quintana, J. Loscertales, P. Martin-Jimenez, and C. Munoz Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia J. Leukoc. Biol., June 1, 2006; 79(6): 1157 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Macor, D. Mezzanzanica, C. Cossetti, P. Alberti, M. Figini, S. Canevari, and F. Tedesco Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res., April 1, 2006; 66(7): 3876 - 3883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Perosa, E. Favoino, M. A. Caragnano, and F. Dammacco Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor Blood, February 1, 2006; 107(3): 1070 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E A Clark and J A Ledbetter How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv77 - iv80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Rotolo, J. Zhang, M. Donepudi, H. Lee, Z. Fuks, and R. Kolesnick Caspase-dependent and -independent Activation of Acid Sphingomyelinase Signaling J. Biol. Chem., July 15, 2005; 280(28): 26425 - 26434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hamaguchi, J. Uchida, D. W. Cain, G. M. Venturi, J. C. Poe, K. M. Haas, and T. F. Tedder The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice J. Immunol., April 1, 2005; 174(7): 4389 - 4399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Niwa, M. Sakurada, Y. Kobayashi, A. Uehara, K. Matsushima, R. Ueda, K. Nakamura, and K. Shitara Enhanced Natural Killer Cell Binding and Activation by Low-Fucose IgG1 Antibody Results in Potent Antibody-Dependent Cellular Cytotoxicity Induction at Lower Antigen Density Clin. Cancer Res., March 15, 2005; 11(6): 2327 - 2336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Friedberg, H. Kim, M. McCauley, E. M. Hessel, P. Sims, D. C. Fisher, L. M. Nadler, R. L. Coffman, and A. S. Freedman Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-{alpha}/{beta}-inducible gene expression, without significant toxicity Blood, January 15, 2005; 105(2): 489 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Friedberg Unique Toxicities and Resistance Mechanisms Associated with Monoclonal Antibody Therapy Hematology, January 1, 2005; 2005(1): 329 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Stel, B.-J. Kroesen, S. Jacobs, H. Groen, L. F. M. H. de Leij, H. C. Kluin-Nelemans, and S. Withoff The Role of B Cell-Mediated T Cell Costimulation in the Efficacy of the T Cell Retargeting Bispecific Antibody BIS20x3 J. Immunol., November 15, 2004; 173(10): 6009 - 6016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cartron, H. Watier, J. Golay, and P. Solal-Celigny From the bench to the bedside: ways to improve rituximab efficacy Blood, November 1, 2004; 104(9): 2635 - 2642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Teeling, R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. H. I. Parren, C. E. Hack, M. Dechant, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas Blood, September 15, 2004; 104(6): 1793 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dall'Ozzo, S. Tartas, G. Paintaud, G. Cartron, P. Colombat, P. Bardos, H. Watier, and G. Thibault Rituximab-Dependent Cytotoxicity by Natural Killer Cells: Influence of FCGR3A Polymorphism on the Concentration-Effect Relationship Cancer Res., July 1, 2004; 64(13): 4664 - 4669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Uchida, Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor-dependent Mechanisms during Anti-CD20 Antibody Immunotherapy J. Exp. Med., June 21, 2004; 199(12): 1659 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li, L. M. Ayer, M. J. Polyak, C. M. Mutch, R. J. Petrie, L. Gauthier, N. Shariat, M. J. Hendzel, A. R. Shaw, K. D. Patel, et al. The CD20 Calcium Channel Is Localized to Microvilli and Constitutively Associated with Membrane Rafts: ANTIBODY BINDING INCREASES THE AFFINITY OF THE ASSOCIATION THROUGH AN EPITOPE-DEPENDENT CROSS-LINKING-INDEPENDENT MECHANISM J. Biol. Chem., May 7, 2004; 279(19): 19893 - 19901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Cragg and M. J. Glennie Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents Blood, April 1, 2004; 103(7): 2738 - 2743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Kennedy, P. V. Beum, M. D. Solga, D. J. DiLillo, M. A. Lindorfer, C. E. Hess, J. J. Densmore, M. E. Williams, and R. P. Taylor Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia J. Immunol., March 1, 2004; 172(5): 3280 - 3288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Hong, R. D. Hansen, J. Yan, D. J. Allendorf, J. T. Baran, G. R. Ostroff, and G. D. Ross {beta}-Glucan Functions as an Adjuvant for Monoclonal Antibody Immunotherapy by Recruiting Tumoricidal Granulocytes as Killer Cells Cancer Res., December 15, 2003; 63(24): 9023 - 9031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. T. C. Chan, D. Hughes, R. R. French, A. L. Tutt, C. A. Walshe, J. L. Teeling, M. J. Glennie, and M. S. Cragg CD20-induced Lymphoma Cell Death Is Independent of Both Caspases and Its Redistribution into Triton X-100 Insoluble Membrane Rafts Cancer Res., September 1, 2003; 63(17): 5480 - 5489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Di Gaetano, E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna, and J. Golay Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo J. Immunol., August 1, 2003; 171(3): 1581 - 1587. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
R-bearing cells, such as ADCC
effector cells, or with anti-CD20 mAb multimers.
) or EHRB (
) cells
(1 × 106/mL) were incubated with mAbs (10 µg/mL) for
15 minutes at room temperature. Normal human serum (NHS, 20%
vol/vol) was then added as a source of complement and the
cells incubated at 37°C for 30 minutes. Cell lysis was
assessed by flow cytometry using a PI exclusion assay, and the level of
CDC expressed as PI-positive cells as a percentage of total cells. The
results show the means and SDs of 3 separate experiments. (B) Surface
expression of CD20, CD37, CD38, and MHCII antigens on Daudi or EHRB
cells. Daudi or EHRB cells (5 × 105/mL) were incubated
with mAbs (10 µg/mL) for 30 minutes at room temperature, then washed
and incubated with goat anti-mouse IgG F(ab')2 FITC for 30 minutes on ice, prior to washing and analysis by flow cytometry.
) or
37°C (
;
Triton X-100 lysis before staining). Shown are the mean fluorescence
intensity (MFI) values for each sample. Error bars show ± SD of triplicate samples.
